-
公开(公告)号：US20160318928A1
公开(公告)日：2016-11-03
申请号：US15107652
申请日：2014-12-23
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Derek J. Norris , George V. Delucca , Ashvinikumar V. Gavai , Claude A. Quesnelle , Patrice Gill , Daniel O'Malley , Wayne Vaccaro , Francis Y. Lee , Mikkel V. DeBenedetto , Andrew P. Degnan , Haiquan Fang , Matthew D. Hill , Hong Huang , William D. Schmitz , John E. Starrett, JR. , Wen-Ching Han , John S. Tokarski , Sunil Kumar Mandal
IPC: C07D471/04 , A61K31/501 , A61K31/506 , A61K31/437 , A61K31/444
CPC classification number: C07D471/04 , A61K31/437 , A61K31/444 , A61K31/501 , A61K31/506
Abstract: The present invention is directed to tricyclic compounds (I), pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
-
公开(公告)号：US20150274734A1
公开(公告)日：2015-10-01
申请号：US14433693
申请日：2013-10-14
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Andrew P. Degnan
IPC: C07D487/04
CPC classification number: C07D487/04
Abstract: The disclosure generally relates to the novel compounds of formula I, including pharmaceutically acceptable salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD). [INSERT CHEMICAL STRUCTURE HERE]
Abstract translation: 本公开内容通常涉及式I的新化合物，其包括药学上可接受的盐，其为CGRP受体拮抗剂。 本公开还涉及用于治疗CGRP相关疾病（包括偏头痛和其他头痛，神经源性血管舒张，神经源性炎症，热损伤，循环休克，与更年期相关的潮红，气道炎症性疾病如哮喘）的药物组合物和方法， 和慢性阻塞性肺疾病（COPD）。 [此处插入化学结构]
-
公开(公告)号：US20160176864A1
公开(公告)日：2016-06-23
申请号：US14580355
申请日：2014-12-23
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Derek J. Norris , George V. Delucca , Ashvinikumar V. Gavai , Claude A. Quesnelle , Patrice Gill , Daniel O'Malley , Wayne Vaccaro , Francis Y. Lee , Mikkel V. DeBenedetto , Andrew P. Degnan , Haiquan Fang , Matthew D. Hill , Hong Huang , William D. Schmitz , John E. Starrett, JR. , Wen-Ching Han , John S. Tokarski , Sunil Kumar Mandal
IPC: C07D471/04 , A61K31/437
CPC classification number: C07D471/04 , A61K31/437 , A61K45/06 , A61K2300/00
Abstract: The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
-
公开(公告)号：US11166959B2
公开(公告)日：2021-11-09
申请号：US16761449
申请日：2018-11-05
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Erika M. V. Araujo , Yan Chen , Bireshwar Dasgupta , Andrew P. Degnan , Matthew D. Hill , Godwin Kwame Kumi , Harold A. Mastalerz , Mark D. Wittman , Bradley C. Pearce , Guifen Zhang
IPC: A61K31/5377 , A61K31/506 , A61P35/00 , A61K45/06 , C07D405/12 , C07D405/14 , C07D413/14 , C07D453/02 , C07D491/048 , C07D498/10 , C07D519/00
Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein: X is CH or N; Y is CR5 or N; and R1, R2, R3, R4, and R5 are defined herein. Also disclosed are methods of using such compounds to modulate or inhibit the enzymatic activity of hematopoietic progenitor kinase 1 (HPK1), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
-
公开(公告)号：US09751879B2
公开(公告)日：2017-09-05
申请号：US15219611
申请日：2016-07-26
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Derek J. Norris , George V. Delucca , Ashvinikumar V. Gavai , Claude A. Quesnelle , Patrice Gill , Daniel O'Malley , Wayne Vaccaro , Francis Y. Lee , Mikkel V. DeBenedetto , Andrew P. Degnan , Haiquan Fang , Matthew D. Hill , Hong Huang , William D. Schmitz , John E. Starrett, Jr. , Wen-Ching Han , John S. Tokarski , Sunil Kumar Mandal
IPC: C07D471/04 , A61K31/437
CPC classification number: C07D471/04 , A61K31/437 , A61K45/06 , A61K2300/00
Abstract: The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
-
Patent Agency Ranking
公开(公告)号：US20160333013A1
公开(公告)日：2016-11-17
申请号：US15150492
申请日：2016-05-10
Applicant: Bristol-Myers Squibb Company
Inventor： Derek J. Norris , Wayne Vaccaro , Mikkel V. DeBenedetto , Andrew P. Degnan , George V. Delucca , Jeffrey A. Deskus , Wen-Ching Han , Godwin Kwame Kumi , William D. Schmitz , John E. Starrett, JR. , Matthew D. Hill , Hong Huang
IPC: C07D471/14 , A61K31/5377 , A61K31/496 , A61K31/444 , A61K31/541 , A61K31/675 , A61K31/4545 , C07D519/00 , A61K31/439 , A61K31/554 , C07F9/6561 , A61K31/683 , A61K31/4375 , A61K31/519
CPC classification number: C07D471/14 , A61K31/4375 , A61K31/439 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/519 , A61K31/5377 , A61K31/541 , A61K31/554 , A61K31/675 , A61K31/683 , C07D519/00 , C07F9/6561
Abstract: The present invention is directed to tricyclic compounds of the formula wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
Abstract translation: 其中所有取代基在本文中定义，以及包含本发明化合物的药学上可接受的组合物以及使用所述组合物治疗各种疾病的方法。
-
公开(公告)号：US20160326173A1
公开(公告)日：2016-11-10
申请号：US15219611
申请日：2016-07-26
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Derek J. Norris , George V. Delucca , Ashvinikumar V. Gavai , Claude A. Quesnelle , Patrice Gill , Daniel O'Malley , Wayne Vaccaro , Francis Y. Lee , Mikkel V. DeBenedetto , Andrew P. Degnan , Haiquan Fang , Matthew D. Hill , Hong Huang , William D. Schmitz , John E. Starrett, JR. , Wen-Ching Han , John S. Tokarski , Sunil Kumar Mandal
IPC: C07D471/04 , A61K31/437
CPC classification number: C07D471/04 , A61K31/437 , A61K45/06 , A61K2300/00
Abstract: The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
Abstract translation: 本发明涉及三环化合物，包含本发明化合物的药学上可接受的组合物和使用所述组合物治疗各种疾病的方法。
-
公开(公告)号：US09725449B2
公开(公告)日：2017-08-08
申请号：US15150492
申请日：2016-05-10
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Derek J. Norris , Wayne Vaccaro , Mikkel V. DeBenedetto , Andrew P. Degnan , George V. Delucca , Jeffrey A. Deskus , Wen-Ching Han , Godwin Kwame Kumi , William D. Schmitz , John E. Starrett, Jr. , Matthew D. Hill , Hong Huang
IPC: C07D471/14 , A61K31/4375 , A61K31/439 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/519 , A61K31/5377 , A61K31/541 , A61K31/554 , A61K31/675 , A61K31/683 , C07D519/00 , C07F9/6561
CPC classification number: C07D471/14 , A61K31/4375 , A61K31/439 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/519 , A61K31/5377 , A61K31/541 , A61K31/554 , A61K31/675 , A61K31/683 , C07D519/00 , C07F9/6561
Abstract: The present invention is directed to tricyclic compounds of the formula wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
-
![Substituted imidazo[1,5-a]pyrazines as CGRP receptor antagonists](/abs-image/US/2017/07/04/US09695176B2/abs.jpg.150x150.jpg)
公开(公告)号：US09695176B2
公开(公告)日：2017-07-04
申请号：US14433693
申请日：2013-10-14
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Andrew P. Degnan
IPC: A61K31/4985 , C07D487/04
CPC classification number: C07D487/04
Abstract: The disclosure generally relates to the novel compounds of formula I, including pharmaceutically acceptable salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD).
-
![IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS](/abs-image/US/2024/02/29/US20240067638A1/abs.jpg.150x150.jpg)
10.发明公开公开(公告)号：US20240067638A1
公开(公告)日：2024-02-29
申请号：US18042036
申请日：2021-08-18
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： David S. Yoon , Alicia Regueiro-Ren , Andrew P. Degnan , Gang WU
IPC: C07D471/04
CPC classification number: C07D471/04
Abstract: The present invention relates to imidazo[1,2-a]pyridine and [1,2,4]triazolo[1, 5-a]pyridine derivatives of formula (I) or a salt thereof. The present compounds are inhibitors of TLR9 and useful in treating preventing, or slowing fibrotic diseases, such as e.g. liver fibrosis, renal fibrosis, biliary fibrosis or pancreatic fibrosis, nonalcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC), or idiopathic pulmonary fibrosis (IPF).
-
-
-
-
-
-
-
-
-
Search Results
17
records
(took 0.077 seconds)
